Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-06
2007-03-06
Nickol, Gary B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S402000
Reexamination Certificate
active
10349977
ABSTRACT:
The present invention generally concerns novel proteins which bind to the intracellular domains of the p55 and p75 TNF-Rs and the FAS-R, which are capable of modulating the function of the p55 and p75 TNF-Rs and the FAS-R, and the DNA sequences which encode them. The present invention also concerns new soluble oligomeric TNF-Rs, oligomeric FAS-Rs and oligomeric receptors having a mixture of TNF-Rs and FAS-Rs. In addition, the present invention concerns methods of preparation and uses of all of the aforementioned.
REFERENCES:
patent: 5395760 (1995-03-01), Smith et al.
patent: 5563039 (1996-10-01), Goeddel et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5632734 (1997-05-01), Galel et al.
patent: 5674734 (1997-10-01), Leder et al.
patent: 5847099 (1998-12-01), Lin et al.
patent: 0 393 438 (1990-10-01), None
patent: 0 417 563 (1991-03-01), None
patent: 0 418 014 (1991-03-01), None
patent: 0 510 691 (1992-10-01), None
patent: 03-133382 (1993-06-01), None
patent: 05-184368 (1993-07-01), None
patent: 06-022786 (1994-02-01), None
Banner et al, “Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation”,Cell73(3):432-445 (1993).
Boldin et al, “A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain”,J Biol Chem270(14):7794-7798 (1995).
Chinnaiyan et al, “FADD , a Novel Death Domain-Containing Protein, Interacts with the Death Domain of Fas and Intiates Apoptosis”,Cell81:505-512 (1995).
Clement et al, “Fas and Tumor Necrosis Factor Receptor-mediated Cell Death: Similarities and Distinctions”,J Exp Med180:557-567 (1994).
Darnay et al, “Physical and Functional Association of a Serine-Threonine Protein Kinase to the Cytoplasmic Domain of the p80 Form of the Human Tumor Necrosis Factor Receptor in Human Histiocytic Lymphoma U-937 Cells”,J Biol Chem269(31):19687-19690 (1994).
Evans et al, “Protective Effect of 55- but not 75-kD Soluble Tumor Necrosis Factor Receptor-Immunoglobulin G Fusion Proteins in an Animal Model of Gram-negative Sepsis”J Exp Med180:2173-2179 (1994).
Hsu et al, “Differential Expression and Ligand Binding Properties of Tumor Necrosis Factor Receptor Chimeric Mutants”,J Biol Chem268(22):16430-16436 (1993).
Hsu et al, “The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF-kB Activation”,Cell81:495-504 (1995).
Itoh et al, “A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen”,J Biol Chem268(15):10932-10937 (1993).
Lewis et al, “Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is specifies specific”,Proc Natl Acad Sci USA88:2830-2834 (1991).
Morimoto et al, “Overcoming Tumor Necrosis Factor and Drug Resistance of Human Tumor Cell Lines by Combination Treatment with Anti-Fas Antibody and Drugs or Toxins”,Cancer Res53:2591-2596 (1993).
Rothe et al, “A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor”,Cell78:4 681-692 (1994).
Song et al, “Aggregation of the intracellular domain of the type 1 tumor necrosis factor receptor defined by the two-hybrid system”,J Biol Chem269(36):22492-22495 (1994).
Song et al, “Identification of a Protein with Homology to hsp90 That Binds the Type 1 Tumor Necrosis Factor Receptor”,J Biol Chem270(8):3574-3581 (1995).
Stanger et al, “RIP: A Novel Protein Containing a Death Domain That Interacts with Fas/APO-1 (CD95) in Yeast and Causes Celll Death”,Cell81:513-523 (1995).
Suda et al, “Molecular Cloning and Expression of the Fas Ligand, a Novel Member of the tumor Necrosis Factor Family”,Cell75:1169-1178 (1993).
Tartaglia et al, “Tumor Necrosis Factor Receptor Signaling: A Dominant Negative Mutation Suppresses the Activation of the 55-KDA Tumor Necrosis Factor Receptor”,J Biol Chem267(7):4304-4307 (1992).
Tartaglia et al, “A novel domain with the 55 kd TNF receptor signals cell death”,Cell74(5):845-853 (1993).
Van Aelst et al, “Complex formation between RAS and RAF and other protein kinases”,Proc Natl Acad Sci USA90:6213-6217 (1993).
Gray et al, “Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein,” Proc Natl Acad Sci USA 87(19):7380-7384 (1990).
Boldin Mark
Mett Igor
Varfolomeev Eugene
Wallach David
Browdy and Neimark PLLC
Jiang Dong
Nickol Gary B.
Yeda Research and Development Co. Ltd.
LandOfFree
Modulator of TNF/NGF superfamily receptors and soluble... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulator of TNF/NGF superfamily receptors and soluble..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulator of TNF/NGF superfamily receptors and soluble... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3790553